Change Condition: Overt HE
IBS-D  
video

Videos & Podcasts

Clinicians discuss managing overt HE and how they connect with patients

Access insights >
resources

Resource Center

Multimedia and clinical resources to aid in discussions with patients, overt HE diagnosis, and ongoing management

View resources >
calender

Events Calendar

Upcoming live and virtual events with content that may be relevant for your practice

See events >

Popular on GastroHub Overt HE

Direct access to resources for managing overt HE.

Overt Hepatic Encephalopathy Management Guide

Overt HE Management Guide

Quick-hit guide about XIFAXAN that highlights efficacy and safety data, dosing, and the steps to complete a prior authorization. Download and share this guide with colleagues who may less frequently manage adult patients at risk of overt HE recurrence.

Download PDF >
Overt Hepatic Encephalopathy Special Report

Overt HE Special Report

Features an overview of overt HE management and clinical highlights from Arun Jesudian, MD, about real-world evidence data and Corrie Berk, DNP, MBA, about the importance of transitions of care in patients with HE.

Download PDF >
Overt Hepatic Encephalopathy Case Study Video, Susan

Management Considerations After an Overt HE Episode

Follow along on the journey of Susan, who presents with a recurrent overt HE episode after being hospitalized for overt HE and requires improved management from her hepatologist.

 

Watch video >
Overt Hepatic Encephalopathy Case Study Video, Carlos

Reducing the Risk of Recurrence Following an Overt HE Hospitalization

Follow along on the journey of Carlos, who was recently hospitalized for an overt HE episode and followed up with his primary care provider due to another episode.

Watch video >
Patient Case Study Videos Handout

Patient Case Study Videos Handout

Download and share this handout with your peers to direct them to overt HE and IBS-D patient case studies presented by practicing APPs.

Download PDF >
Visit Resource Center

<

Request a Rep for Overt HE Treatment Questions for Nurse Practitioners (NPs) and Physician Assistants (PAs)

Have questions? Request a rep.

A representative can schedule a time to visit your practice or assist you with ordering samples and accessing patient support materials.

Request a rep >

Don’t miss new resources!

Sign up to stay informed of updates to GastroHub.

Sign Up Now
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
    • HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)
    • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

XIF.0166.USA.24

SEE MORE

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.